Gapping up
In reaction to strong earnings/guidance:
- AUDC +16.4%, DB +10.6%, IHG +4.1% (Trading update) DORM +3.5%, CHKP +1.9%, CNX +1.4%
Select index ETFs showing strength:
- IWM +1.5%, QQQ +1.3%, SPY +1%, DIA +0.9%, .
Other news:
- AXSM +42.7% (announces AXS-05 achieves primary endpoint in the ADVANCE-1 pivotal phase 2/3 trial in alzheimer's disease agitation)
- AVDL +37.3% (announced positive topline data from its pivotal Phase 3 REST-ON trial of FT218 for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy)
- ARCT +16.1% (announces positive immunogenicity data from its preclinical study for the Company's COVID-19 Vaccine)
- RDHL +11.3% (reports preliminary data in moderate-to-severe COVID-19 patients treated with opaganib show measurable clinical improvement in all six patients analyzed)
- HALO +6.5% (Halozyme Therapeutics announces JNJ's Janssen submits New Drug Application in Japan for daratumumab subcutaneous formulation utilizing Halozyme's ENHANZE)
- FLXN +5.9% (announces new positive preclinical efficacy and pharmacokinetic data for FX301)
- KMDA +4.9% (Kamada and Kedrion Biopharma announce a collaboration for the development, manufacturing and distribution of a human plasma-derived Anti-SARS-CoV-2 (COVID-19) polyclonal immunoglobulin (IgG) product as a potential treatment for coronavirus patients)
- BHVN +3.2% (Biohaven Pharmaceutical and Genpharm Services announce agreement distribute NURTEC ODT (rimegepant) in the Middle East and Gulf countries)
- ATEC +3.1% (Terminates agreement to acquire EOS Imaging)
- NBIX +2.9% (receives FDA approval of once-daily oral ONGENTYS)
- SNY +2.3% (Regeneron Pharma and Sanofi announces preliminary results from U.S. Phase 2/3 adaptive-designed trial in hospitalized COVID-19 patients)
- TSLA +1.8% (asks dozens of people to return to work Wednesday)
- BA +1.4% (modestly rebounding following Friday's slide; also terminates agreement to establish joint ventures with Embraer)
- AZN +1.1% (reports FDA approved a label update in the US for LOKELMA)
Analyst comments:
- LH +4.4% (upgraded to Buy from Neutral at Citigroup)
- FCX +3.2% (upgraded to Sector Outperform from Sector Perform at Scotiabank)
- PAG +2.3% (upgraded to Buy from Neutral at Northcoast)
- AN +2.1% (upgraded to Buy from Neutral at Northcoast)
- EBAY +2.1% (upgraded to Neutral from Underperform at Mizuho)
- TWTR +1.9% (upgraded to Neutral from Underperform at Mizuho)
- ADS +1.5% (upgraded to Buy from Neutral at Compass Point)